Axial Spondyloarthritis (AxSpA) Market Report 2025

The axial spondyloarthritis (axspa) market size has grown strongly in recent years. It will grow from $6.08 billion in 2024 to $6.58 billion in 2025 at a compound annual growth rate (CAGR) of 8.3%. The growth in the historic period can be attributed to improved diagnostic criteria, biological treatment advancements, rising disease awareness, genetic research advances, clinical trial progress.

The axial spondyloarthritis (axspa) market size is expected to see strong growth in the next few years. It will grow to $9.05 billion in 2029 at a compound annual growth rate (CAGR) of 8.3%. The growth in the forecast period can be attributed to advancements in biomarker identification, tailored therapies, digital health integration, expanded treatment options, healthcare policy support. Major trends in the forecast period include early intervention strategies, patient-centric care, telemedicine and remote consultations, research on disease mechanisms, shared decision-making.

The rising prevalence of spondyloarthritis is expected to be a driving force behind the growth of the axial spondyloarthritis (axSpa) market. Spondyloarthritis, a chronic condition primarily affecting the axial skeleton, such as the spine and sacroiliac joints, has seen an increase in cases linked to the aging population and spinal injuries resulting from minor falls or accidents. Various treatments aim at managing pain, controlling inflammation, and improving the quality of life for individuals suffering from axSpA. For example, according to Versus Arthritis's Musculoskeletal Health Report 2023, a UK-based charity supporting people with arthritis, approximately 60,000 individuals were affected by axial spondyloarthritis in 2022, with around 2,200 adults diagnosed annually with this condition. Hence, the rising prevalence of axial spondyloarthritis is a significant driver fueling the growth of the axSpa market.

The growing aging population is anticipated to drive the expansion of the axial spondyloarthritis (axSpA) market in the future. An aging population refers to a demographic shift where the proportion of elderly individuals within a population increases. Managing axSpA in older adults offers several benefits, including improved joint function and mobility, enhanced quality of life, prevention of spinal structural damage, reduced healthcare costs, prevention of disability, and optimized treatment approaches. For instance, in October 2022, the World Health Organization reported that by 2030, 1 in 6 people globally will be aged 60 or older, with this figure expected to double to 2.1 billion by 2050. Furthermore, in July 2023, Age UK, a UK-based charity, noted that there are currently 11 million people over the age of 65 in England, with this number projected to rise by 10% over the next five years and by 32% by 2043, equating to increases of 1.1 million and 3.5 million people, respectively. As a result, the rising aging population is fueling the growth of the axial spondyloarthritis (axSpA) market.

Product innovation stands out as a leading trend gaining traction in the axial spondyloarthritis (axSpA) market. Key companies in this field are actively developing novel drugs to maintain their market standing. For instance, in June 2023, UCB SA, a pharmaceutical company based in Belgium, obtained marketing authorization from the New European Commission for BIMZELX (bimekizumab). This medication is designed for treating active axial spondyloarthritis (axSpA), non-radiographic axial spondyloarthritis (nr-axSpA), and ankylosing spondylitis (AS) in adults exhibiting objective signs of inflammation indicated by elevated C-reactive protein. These approvals within the European Union represent the first global marketing authorizations for the treatment of axial spondyloarthritis using this drug.

Significant investments are a focal point for major companies operating in the axial spondyloarthritis (axSpA) market to gain a competitive advantage. Notably, the investment revolves around the development of Izokibep, a unique IL-17A inhibitor intended for managing inflammatory diseases such as psoriatic arthritis (PsA) and axial spondyloarthritis (AxSpA). For example, in September 2022, Acelyrin Inc., a biopharmaceutical company based in the US, announced a $300 million investment. Izokibep, a mimetic antibody simulating interleukin-17A (IL-17A), aims to overcome the limitations of monoclonal antibodies and has shown promising tolerability in clinical trials. This substantial investment is directed towards securing potential approvals for Izokibep as a treatment for various inflammatory conditions and advancing its clinical development. The company's commitment to pioneering immunology therapies and addressing unmet medical needs in treating inflammatory disorders is evident through its emphasis on securing significant funding and advancing the development of Izokibep.

In April 2022, Ampersand Health, a UK-based research company, entered into a partnership with UCB SA for an undisclosed amount. This collaboration is intended to benefit patients dealing with axial spondyloarthritis (axSpA) by leveraging the innovative digital solutions from Ampersand Health and the clinical expertise of UCB SA. The aim of the partnership is to enhance the management of symptoms for individuals with axial spondyloarthritis and improve their overall quality of life. UCB SA, the Belgium-based biopharmaceutical company involved in neurology and immunology therapies, is known for providing solutions in the field of axial spondyloarthritis.

Major companies operating in the axial spondyloarthritis (axSpA) market include Johnson and Johnson Private Limited, Pfizer Inc., F. Hoffmann-La Roche AG, Merck and Co. Inc., AbbVie Inc., Novartis AG, Sanofi S.A, Bristol-Myers Squibb Company, AstraZeneca plc., Abbott Laboratories, GSK plc., Eli Lilly and Company, Takeda Pharmaceutical Company Limited, Gilead Sciences Inc., Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Biogen Inc., Vertex Pharmaceuticals Incorporated, UCB S.A., Boehringer Ingelheim International GmbH., Horizon Therapeutics Public Ltd Co, Mitsubishi Tanabe Pharma Corporation, Ipsen Technologies Pvt Ltd., Kyowa Kirin Co. Ltd., Sun Pharmaceutical Industries Ltd., Acelyrin Inc., Nordic Bioscience A/S, Iroko Pharmaceuticals LLC.

North America was the largest region in the axial spondyloarthritis (axSpA) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the axial spondyloarthritis (axspa) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the axial spondyloarthritis (axspa) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

Axial Spondyloarthritis (axSpA) is a chronic inflammatory condition primarily affecting the axial skeleton, including the spine and sacroiliac joints, leading to persistent back pain and stiffness. The condition is characterized by inflammation in the sacroiliac joints.

The main types of axial spondyloarthritis (axSpA) include Ankylosing Spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA). Ankylosing Spondylitis (AS) is a specific form of arthritis that affects the ligaments and joints in the spine. Commonly used over-the-counter anti-inflammatory medications, such as naproxen and ibuprofen, are often employed to alleviate pain, inflammation, and muscle stiffness, with the goal of delaying complications and spinal deformities. Various commercialized therapies are available for the treatment of axial spondyloarthritis, including anti-tumor necrosis factor therapy (TNF), anti-interleukin therapy (IL), and anti-janus kinase therapy (JAK). These therapies come in different dosage forms, such as tablets and injections, and are utilized for different types of treatments, including tumor necrosis factor (TNF) alpha inhibitors, non-steroidal anti-inflammatory drugs (NSAID), conventional disease-modifying anti-rheumatic drugs, glucocorticoids, and interleukin blockers. These treatments are distributed through different channels, including hospital pharmacies, retail pharmacies, and online pharmacy stores.

The axial spondyloarthritis (axSpA) market research report is one of a series of new reports that provides axial spondyloarthritis (axSpA) market statistics, including axial spondyloarthritis (axSpA) industry global market size, regional shares, competitors with an axial spondyloarthritis (axSpA) market share, detailed axial spondyloarthritis (axSpA) market segments, market trends and opportunities, and any further data you may need to thrive in the axial spondyloarthritis (axSpA) industry. This axial spondyloarthritis (axSpA) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The axial spondyloarthritis (axSpA) market consists of revenues earned by entities by providing physical examinations, blood tests, magnetic resonance imaging (MRI) scans, and X-ray scans. The market value includes the value of related goods sold by the service provider or included within the service offering. The axial spondyloarthritis (axSpA) market also includes sales of analgesics, biologics, ibuprofen, naproxen, and diclofenac. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.